Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble(Cedars-Sinai Medical Center), Roland M. du Bois(Imperial College London), David Kardatzke(InterScience (United States)), Talmadge E. King(University of California, San Francisco), Dominique Valeyre(Inserm), Williamson Z. Bradford(InterScience (United States)), Carlo Albera(University of Turin), Marilyn K. Glassberg(University of Miami), Ulrich Costabel(Ruhrlandklinik), Steven A. Sahn(Medical University of South Carolina), Javier Szwarcberg(InterScience (United States)), Lisa Lancaster(Vanderbilt University Medical Center)
Cited by 2,148
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
|Immunity|2009|2.3k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k
Sarcoidosis
|The Lancet|2013|1.1k
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
|European Respiratory Journal|2005|1k